1.1 Ethical Standards and Research Integrity

All submissions to Advanced Drug Sciences (ADS) must comply with internationally recognized standards of research integrity and publication ethics, including those outlined by the Committee on Publication Ethics (COPE).

Authors are required to ensure that:

• The work is original and has not been fabricated, falsified, or manipulated
• All data are presented accurately and transparently
• Proper acknowledgment is given to prior work through appropriate citation
• The manuscript does not contain plagiarized or substantially overlapping content

The journal employs similarity detection systems to evaluate originality. Manuscripts exhibiting significant overlap, redundant publication, or unethical practices will be rejected without peer review.

Confirmed cases of misconduct may result in:

• Rejection or retraction of the manuscript
• Notification to the authors’ affiliated institutions
• Restrictions on future submissions

1.2 Studies Involving Human Participants

Research involving human participants must be conducted in accordance with recognized ethical standards, including the Declaration of Helsinki.

Authors must provide a clear statement in the manuscript confirming that:

• Ethical approval was obtained from a recognized institutional review board or ethics committee
• The approval reference number and date are specified
• The study complies with applicable national and institutional regulations

Additionally, authors must confirm that:

• Informed consent was obtained from all participants prior to inclusion in the study
• Participants’ privacy and confidentiality have been strictly protected

Manuscripts lacking appropriate ethical approval or consent documentation will not be considered for publication.

1.3 Studies Involving Animals

All research involving animals must adhere to established ethical guidelines and regulatory standards governing animal experimentation.

Authors must explicitly state that:

• The study was approved by an appropriate institutional or national ethics committee
• The research complies with relevant animal welfare regulations
• All efforts were made to minimize suffering and reduce the number of animals used

Authors are expected to follow recognized reporting standards such as ARRIVE guidelines where applicable.

Failure to demonstrate ethical compliance will result in rejection of the manuscript.

1.4 Informed Consent and Patient Data

For studies involving human participants, patients, or identifiable personal data:

• Written informed consent must be obtained prior to participation
• Consent must cover publication of clinical details, images, or personal data where applicable
• Identifiable information must be removed unless explicit permission has been granted

Authors must retain all consent documentation and provide it upon request by the editorial office.

The inclusion of identifiable patient information without appropriate consent constitutes a violation of ethical standards and will result in immediate rejection.

1.5 Declaration of Competing Interests

All authors must disclose any financial, professional, or personal relationships that could influence or bias the work.

Authors are required to:

• Declare all relevant competing interests at the time of submission
• Include a dedicated “Conflict of Interest” statement within the manuscript

Examples of competing interests include, but are not limited to:

• Employment or consultancy
• Research funding or grants
• Stock ownership or intellectual property interests
• Honoraria or paid expert testimony

If no competing interests exist, authors must state:

“The authors declare no competing interests.”

Failure to disclose relevant conflicts may result in rejection, correction, or retraction.

1.6 Use of Artificial Intelligence in Scientific Writing

The use of generative artificial intelligence (AI) and AI-assisted technologies in manuscript preparation is subject to strict limitations.

Authors may use such tools only for:

• Improving language clarity
• Enhancing readability

Authors must not use AI tools for:

• Generating scientific content, interpretation, or conclusions
• Data analysis or result generation
• Authorship attribution

If AI tools are used, authors must include a disclosure statement in the manuscript specifying:

• The name of the tool
• The purpose of its use

AI tools cannot be listed as authors under any circumstances.

Authors retain full responsibility for the accuracy, integrity, and originality of the manuscript.

1.7 Submission Declaration and Originality

Submission of a manuscript to ADS constitutes confirmation that:

• The work has not been previously published in any form, except as a preprint, thesis, or abstract
• The manuscript is not under consideration by another journal
• All authors have approved the submission
• The work complies with institutional and regulatory requirements

The journal reserves the right to verify originality using similarity-checking tools.

Duplicate submission or concurrent submission to multiple journals is strictly prohibited and will result in immediate rejection.

1.8 Preprint Policy

ADS permits submission of manuscripts that have been previously posted on recognized preprint servers.

Authors must:

• Disclose the existence of a preprint at the time of submission
• Provide the DOI or link to the preprint version

Preprints are not considered prior publication.

However, authors must ensure that:

• The submitted manuscript reflects the version intended for peer review
• The preprint is not updated to include peer-reviewed content prior to formal publication

1.9 Inclusive Language and Scientific Neutrality

Authors must ensure that manuscripts are written using inclusive, respectful, and unbiased language.

Manuscripts should:

• Avoid discriminatory or stereotypical expressions
• Use terminology that is scientifically accurate and culturally appropriate
• Refrain from unnecessary reference to personal attributes such as gender, ethnicity, or age unless scientifically relevant

The use of biased or inappropriate language may result in revision requests prior to peer review.

1.10 Sex- and Gender-Based Reporting

For research involving humans, animals, or biological systems, authors must:

• Clearly define and distinguish between sex and gender where applicable
• Describe how sex and/or gender variables were considered in study design and analysis
• Report findings disaggregated by sex or gender where relevant

If such analysis is not conducted, authors must provide a justification and discuss this as a limitation.

Accurate reporting of sex and gender enhances the reproducibility and applicability of research findings.

1.11 Changes to Authorship

Authorship must be determined prior to initial submission and must accurately reflect the contributions of all individuals involved in the work.

Authors are required to:

• Provide the complete and final list of authors at the time of submission
• Ensure that all listed authors meet the authorship criteria defined by the International Committee of Medical Journal Editors (ICMJE).
• Confirm that all authors have reviewed and approved the submitted version of the manuscript

Any request to modify the authorship (including addition, removal, or rearrangement of author names) must be submitted before the manuscript is formally accepted.

Such requests must include:

• A clear and detailed justification for the proposed change
• Written confirmation (email or formal letter) from all listed authors, including any author being added or removed, indicating agreement with the change

Post-acceptance changes to authorship are not permitted under any circumstances.

Requests submitted after acceptance will not be considered, except in cases of demonstrable editorial or administrative error.

1.12 Copyright, Licensing, and Permissions

Advanced Drug Sciences (ADS) is an open access journal. Authors retain copyright of their published work.

Upon acceptance of a manuscript:

• Authors will be required to agree to the journal’s licensing terms
• Articles will be published under an open access license that permits distribution and reuse in accordance with the selected license conditions

1.12.1 Use of Third-Party Material

If the manuscript includes any material that is not original to the authors (including but not limited to figures, tables, images, graphical elements, or substantial text excerpts), authors must:

• Obtain written permission from the original copyright holder prior to submission
• Ensure that the permission covers reuse in an open access publication
• Provide appropriate attribution within the manuscript

Authors must upload all permission documents during submission or upon request by the editorial office.

Failure to provide valid permissions may result in:

• Delay in publication
• Removal of the material
• Rejection of the manuscript, where necessary

1.13 Funding Disclosure

Authors must disclose all sources of financial support related to the research described in the manuscript.

The funding statement must:

• Be included in a dedicated section of the manuscript
• Clearly identify all funding organizations using their official names
• Include grant numbers where applicable
• Specify the role of the funding body in study design, data collection, analysis, and publication decisions

Where no external funding was received, authors must include the statement:

“This research received no external funding.”

Incomplete or misleading funding disclosures may result in rejection or post-publication correction.

1.14 Responsibility and Accountability

Authors bear full responsibility for the content of their submitted and published work.

By submitting a manuscript, authors confirm that:

• All data presented are accurate and have not been manipulated in a misleading manner
• The study has been conducted in accordance with accepted scientific and ethical standards
• All authors take public responsibility for the integrity of the work

The journal, publisher, and editorial team do not assume responsibility for:

• The application of methods or findings described in the publication
• Any consequences arising from the use of published information

Authors are encouraged to ensure independent validation of findings where appropriate.

1.15 Compliance and Enforcement

Compliance with the journal’s policies is mandatory.

The editorial office reserves the right to:

• Reject manuscripts that do not meet ethical, scientific, or formatting requirements
• Request additional documentation or clarification at any stage of the review process
• Withdraw acceptance if serious issues are identified prior to publication
• Issue corrections, retractions, or expressions of concern in accordance with COPE guidelines

Authors are expected to cooperate fully with all editorial and ethical inquiries.

1.16 Author Rights

Authors publishing in Advanced Drug Sciences (ADS) retain copyright of their work, subject to the terms of the journal’s open access licensing policy.

Upon acceptance and publication, authors are granted the following rights:

• The right to share, distribute, and communicate their published article in accordance with the applicable open access license
• The right to deposit the published version or accepted manuscript in institutional or subject repositories
• The right to reuse figures, tables, and content from their article in future scholarly works, provided appropriate citation is given

Authors are responsible for ensuring that:

• Any third-party material included in the manuscript has been properly licensed or permitted for reuse
• Proper attribution is provided for all reused content

The specific terms of reuse and distribution are governed by the selected open access license under which the article is published.

1.17 Disclaimer

The content published in Advanced Drug Sciences (ADS) is intended solely for academic and research purposes.

Practitioners, researchers, and other users are advised to exercise their own professional judgment and expertise when interpreting and applying the information, methods, compounds, or experimental findings described in published articles.

Due to the evolving nature of scientific knowledge, particularly in biomedical and pharmaceutical sciences, independent verification of experimental procedures, clinical practices, and drug-related information, including dosages and safety considerations, is strongly recommended.

To the fullest extent permitted by applicable law, the publisher, editors, and affiliated institutions disclaim any liability for:

• Any direct or indirect loss, damage, or injury to persons or property arising from the use or application of information contained in the journal
• Any errors, omissions, or inaccuracies in published content
• Any consequences resulting from reliance on the methods, products, instructions, or ideas described in the publication

Responsibility for the content of each article rests solely with the authors.